COCH vs. INGN, LAKE, CLGN, APT, MLSS, NTRB, RBOT, LFWD, POAI, and HSCS
Should you be buying Envoy Medical stock or one of its competitors? The main competitors of Envoy Medical include Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Alpha Pro Tech (APT), Milestone Scientific (MLSS), Nutriband (NTRB), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Predictive Oncology (POAI), and Heart Test Laboratories (HSCS). These companies are all part of the "surgical appliances & supplies" industry.
Envoy Medical (NASDAQ:COCH) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
Envoy Medical has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Inogen received 383 more outperform votes than Envoy Medical when rated by MarketBeat users. However, 100.00% of users gave Envoy Medical an outperform vote while only 70.44% of users gave Inogen an outperform vote.
Envoy Medical has higher earnings, but lower revenue than Inogen.
Envoy Medical presently has a consensus target price of $6.00, indicating a potential upside of 153.16%. Inogen has a consensus target price of $7.00, indicating a potential downside of 15.66%. Given Envoy Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Envoy Medical is more favorable than Inogen.
In the previous week, Envoy Medical had 1 more articles in the media than Inogen. MarketBeat recorded 3 mentions for Envoy Medical and 2 mentions for Inogen. Inogen's average media sentiment score of 1.43 beat Envoy Medical's score of 0.30 indicating that Inogen is being referred to more favorably in the news media.
Envoy Medical has a net margin of 0.00% compared to Inogen's net margin of -30.07%. Envoy Medical's return on equity of 0.00% beat Inogen's return on equity.
8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 0.7% of Envoy Medical shares are owned by company insiders. Comparatively, 1.0% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Envoy Medical beats Inogen on 10 of the 16 factors compared between the two stocks.
Get Envoy Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Envoy Medical Competitors List
Related Companies and Tools
